S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
NASDAQ:VBLT

Vascular Biogenics - VBLT Stock Forecast, Price & News

$0.15
-0.03 (-17.17%)
(As of 01/27/2023 08:56 PM ET)
Add
Compare
Today's Range
$0.15
▼
$0.20
50-Day Range
$0.11
▼
$0.18
52-Week Range
$0.10
▼
$2.20
Volume
6.87 million shs
Average Volume
1.75 million shs
Market Capitalization
$10.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.17

Vascular Biogenics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
3,365.2% Upside
$5.17 Price Target
Short Interest
Healthy
0.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

629th out of 1,049 stocks

Pharmaceutical Preparations Industry

319th out of 514 stocks

See Top Rated MarketRank™ Stocks Here

VBLT stock logo

About Vascular Biogenics (NASDAQ:VBLT) Stock

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Stock News Headlines

January 30, 2023 | americanbankingnews.com
Vascular Biogenics (NASDAQ:VBLT) Coverage Initiated by Analysts at StockNews.com
January 22, 2023 | americanbankingnews.com
Vascular Biogenics (NASDAQ:VBLT) Coverage Initiated at StockNews.com
January 30, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
November 10, 2022 | finance.yahoo.com
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
September 2, 2022 | finance.yahoo.com
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
September 1, 2022 | finance.yahoo.com
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
September 1, 2022 | finance.yahoo.com
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
August 2, 2022 | marketwatch.com
Vascular Biogenics Cutting About 35% of Staff >VBLT
January 30, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
August 2, 2022 | finance.yahoo.com
VBL Therapeutics Announces Workforce Reduction
July 21, 2022 | finance.yahoo.com
Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails
July 20, 2022 | msn.com
Gold Prices Settle Lower; Vascular Biogenics Shares Plummet
July 20, 2022 | msn.com
Why Is Vascular Biogenics (VBLT) Stock Down 80% Today?
July 20, 2022 | finance.yahoo.com
Read Why VBL Therapeutics Shares Are Falling To a 52-Week Low
July 19, 2022 | finance.yahoo.com
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
May 31, 2022 | finance.yahoo.com
VBL Therapeutics to Participate in the Jefferies Healthcare Conference
May 10, 2022 | finance.yahoo.com
VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17
May 8, 2022 | finance.yahoo.com
What Kind Of Shareholders Hold The Majority In Vascular Biogenics Ltd.'s (NASDAQ:VBLT) Shares?
May 3, 2022 | finance.yahoo.com
VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May
April 26, 2022 | msn.com
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell ...
April 16, 2022 | seekingalpha.com
Vascular Biogenics (VBLT) Presents at the KOL Event on Ovarian Cancer - Slideshow
March 23, 2022 | finance.yahoo.com
VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update
March 22, 2022 | benzinga.com
Vascular Biogenics Earnings Preview
March 22, 2022 | markets.businessinsider.com
Vascular Biogenics earnings: here's what Wall Street expects
March 14, 2022 | finance.yahoo.com
UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23
March 8, 2022 | marketwatch.com
Vascular Biogenics Shares Rise Premarket on Phase 3 Ofra-Vec Study Update >VBLT
March 8, 2022 | finance.yahoo.com
VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned
See More Headlines
Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Company Calendar

Last Earnings
11/14/2022
Today
1/30/2023
Next Earnings (Estimated)
3/22/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VBLT
Previous Symbol
NASDAQ:VBLX
CUSIP
N/A
CIK
1603207
Web
www.vblrx.com
Phone
(728) 993-5000
Fax
972-8993-5001
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.17
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+3,365.2%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.49)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-29,920,000.00
Net Margins
-4,465.93%
Pretax Margin
-4,465.93%
Return on Equity
-99.67%
Return on Assets
-75.60%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.82
Quick Ratio
2.82

Sales & Book Value

Annual Sales
$770,000.00
Price / Sales
13.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.73 per share
Price / Book
0.20

Miscellaneous

Outstanding Shares
69,330,000
Free Float
65,077,000
Market Cap
$10.34 million
Optionable
Optionable
Beta
0.73

Key Executives

  • Dror Harats
    Chief Executive Officer & Director
  • Eyal Breitbart
    Senior Vice President-Research & Operations
  • Erez Feige
    Senior Vice President-Business Operations
  • Samuel I. Backenroth
    Chief Financial Officer
  • Tami Rachmilewitz
    Senior Vice President-Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













VBLT Stock - Frequently Asked Questions

Should I buy or sell Vascular Biogenics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VBLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VBLT, but not buy additional shares or sell existing shares.
View VBLT analyst ratings or view top-rated stocks.

What is Vascular Biogenics' stock price forecast for 2023?

4 Wall Street research analysts have issued 12 month price objectives for Vascular Biogenics' stock. Their VBLT share price forecasts range from $5.00 to $5.50. On average, they predict the company's share price to reach $5.17 in the next twelve months. This suggests a possible upside of 3,365.2% from the stock's current price.
View analysts price targets for VBLT or view top-rated stocks among Wall Street analysts.

How have VBLT shares performed in 2023?

Vascular Biogenics' stock was trading at $0.12 at the beginning of the year. Since then, VBLT shares have increased by 24.3% and is now trading at $0.1491.
View the best growth stocks for 2023 here.

When is Vascular Biogenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our VBLT earnings forecast.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) released its quarterly earnings data on Monday, November, 14th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.01. The biopharmaceutical company earned $0.48 million during the quarter, compared to analyst estimates of $0.15 million. Vascular Biogenics had a negative net margin of 4,465.93% and a negative trailing twelve-month return on equity of 99.67%.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

How do I buy shares of Vascular Biogenics?

Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $0.15.

How much money does Vascular Biogenics make?

Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $10.34 million and generates $770,000.00 in revenue each year. The biopharmaceutical company earns $-29,920,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for the company is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001.

This page (NASDAQ:VBLT) was last updated on 1/30/2023 by MarketBeat.com Staff